β-Blockers are vital in the current management of congenital long QT syndrome, but genotype-specific treatments may be options in the future
Crossref DOI link: https://doi.org/10.1007/s40267-015-0205-1
Published Online: 2015-03-31
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
,
Text and Data Mining valid from 2015-03-31
